Provided by Tiger Fintech (Singapore) Pte. Ltd.

Insmed

97.98
+7.057.75%
Post-market: 97.30-0.6800-0.69%19:58 EDT
Volume:12.74M
Turnover:1.23B
Market Cap:17.85B
PE:-16.65
High:98.95
Open:92.00
Low:90.86
Close:90.93
Loading ...

Jefferies ups Insmed target on ‘blue sky scenario’ PAH data

TIPRANKS
·
Yesterday

Insmed Up Over 27%, on Track for Highest Close Since November 2000 -- Data Talk

Dow Jones
·
Yesterday

Liquidia weakness looks overdone, says BTIG

TIPRANKS
·
10 Jun

Insmed price target raised to $115 from $100 at Leerink

TIPRANKS
·
10 Jun

Insmed Inc : Leerink Partners Raises Target Price to $115 From $100

THOMSON REUTERS
·
10 Jun

Insmed Stock Skyrockets Following Experimental Drug Trial Results -- Barrons.com

Dow Jones
·
10 Jun

Insmed Shares Rise 22% After Positive Mid-Stage Results for Blood Pressure Treatment

THOMSON REUTERS
·
10 Jun

Liquidia, United Therapeutics Shares Fall Pre-Bell After Rival Insmed's Phase 2b PAH Trial Meets Endpoints

MT Newswires Live
·
10 Jun

BUZZ-U.S. STOCKS ON THE MOVE-United Natural Foods, Insmed, MacroGenics

Reuters
·
10 Jun

Insmed Shares Rise on Positive Results From Study of Treatment for High Blood Pressure in Lungs

Dow Jones
·
10 Jun

United Therapeutics falls after Insmed’s TPIP meets endpoints in study

TIPRANKS
·
10 Jun

Insmed Says Phase 2b Trial of Treprostinil Inhalation Powder in PAH Meets Endpoints

MT Newswires Live
·
10 Jun

BUZZ-Insmed soars as blood pressure drug succeeds in mid-stage trial

Reuters
·
10 Jun

Insmed Announces Positive Phase 2b Study Results

TIPRANKS
·
10 Jun

Truist Financial Sticks to Their Buy Rating for Insmed (INSM)

TIPRANKS
·
10 Jun

Insmed Shares Jump 27% Premarket After Positive Mid-Stage Results for Blood Pressure Treatment

THOMSON REUTERS
·
10 Jun

BRIEF-Insmed Announces Positive Topline Results From Phase 2B Study Of Its Blood Pressure Drug

Reuters
·
10 Jun

Insmed's blood pressure drug meets main goal in mid-stage trial

Reuters
·
10 Jun

Insmed’s Inhalation Powder meets endpoints in Phase 2b PAH trial

TIPRANKS
·
10 Jun

Insmed Inc. Announces Positive Phase 2b Study Results for TPIP in PAH, Plans Phase 3 Trials for PH-ILD and PAH by 2026

Reuters
·
10 Jun